Recombinant Human Transforming Growth Factor-β Industry Opportunities and Challenges: A Detailed Global Analysis

The global market for Recombinant Human Transforming Growth Factor-β was estimated to be worth US$ 1639 million in 2024 and is forecast to a readjusted size of US$ 2597 million by 2031 with a CAGR of 6.9% during the forecast period 2025-2031. Recombinant human transforming growth factor-β is a biologically active protein produced by genetic engineering technology. It simulates the function of transforming growth factor-β naturally present in the human body and participates in regulating biological processes such as cell proliferation, differentiation and immune response. It is characterized by high specificity and activity, which can effectively promote cell growth and tissue repair; it has strong controllability during the production process and can be prepared on a large scale to meet clinical and scientific research needs; at the same time, due to its recombinant nature, it avoids the potential risks of animal-derived products. The advantage is that rh-TGF-β provides a new biological drug for clinical treatment, which is used to promote wound healing, treat inflammation and certain diseases, and has important medical value and broad application prospects.